
A Ciba Foundation Symposium

DRUG RESISTANCE IN MICRO-ORGANISMS

Mechanisms of Development

Editors for the Ciba Foundation

G. E. W. WOLSTENHOLME, O.B.E., M.A., M.B., B.Ch.

and

CECILIA M. O'CONNOR, B.Sc.

With 62 Illustrations

J. & A. CHURCHILL LTD.
104 GLOUCESTER PLACE, LONDON, W.1

CIBA FOUNDATION SYMPOSIUM
ON
DRUG RESISTANCE IN
MICRO-ORGANISMS

Mechanisms of Development

Editors for the Ciba Foundation

G. E. W. WOLSTENHOLME, O.B.E., M.A., M.B., B.Ch.

and

CECILIA M. O'CONNOR, B.Sc.

With 62 Illustrations



LONDON
J. & A. CHURCHILL LTD.
104 GLOUCESTER PLACE, W.1
1957

**DRUG RESISTANCE IN
MICRO-ORGANISMS**

Mechanisms of Development

Ciba Foundation Symposia

General Volumes:

Visceral Circulation	—	—	—	—	—	30s.
Mammalian Germ Cells	—	—	—	—	—	30s.
Preservation and Transplantation of Normal Tissues	—	—	—	—	—	25s.
Leukæmia Research	—	—	—	—	—	30s.
Chemistry and Biology of Pteridines	—	—	—	—	—	42s.
Porphyrin Biosynthesis and Metabolism	—	—	—	—	—	30s.
Histamine	—	—	—	—	—	50s.
Extrasensory Perception	—	—	—	—	—	27s. 6d.
Bone Structure and Metabolism	—	—	—	—	—	45s.
Paper Electrophoresis	—	—	—	—	—	35s.
Ionizing Radiations and Cell Metabolism	—	—	—	—	—	45s.
The Nature of Viruses	—	—	—	—	—	42s.
Chemistry and Biology of Purines	—	—	—	—	—	48s.

A leaflet giving fuller details of these volumes, also of the Ciba Foundation Colloquia on Endocrinology and Colloquia on Ageing, is available from the Publishers.

PREFACE

It was Sir Charles Harington, Director of the National Institute for Medical Research, and also Chairman of the Medical Research Council's Committee on Chemotherapy, who put forward to the Director of the Ciba Foundation the proposal of a symposium on drug resistance. It was his belief that the more fundamental problems at the basis of chemotherapy were not attracting as much attention in research as was desirable, and his hope that out of a thorough discussion of the question some suggestions might come which would stimulate fresh investigations, more particularly perhaps on the part of chemists.

The Director of the Foundation thought it would be most profitable, and more in keeping with the facilities of the Foundation, if the subject to be considered were narrowed down to "Mechanisms of Development of Drug Resistance in Micro-Organisms." With the expert advice and ready assistance of Sir Charles, and also of Dr. M. R. Pollock, such a meeting was realized in March 1957, Sir Charles himself acting as its Chairman. The Trustees and the Director of the Foundation remain much indebted to both of them, and to the Members who contributed so freely and informatively in the papers and discussions.

The group was a small one, as usual at the Ciba Foundation, partly because the Foundation's accommodation is severely limited, but mainly because experience has shown that useful discussions can best be conducted when members can get to know each other quickly and well, and can be seated in a convenient and comfortable manner for conversation.

This record of the papers presented and the discussions they aroused is prepared for the many people who could not be invited on this occasion, and the Editors hope it will prove an acceptable substitute for personal participation.

To some readers this book may form an introduction to the work of the Ciba Foundation, and it may be helpful to add a few words about its interests.

Under its eminent Trustees, the Foundation is engaged in a number of activities with the purpose of improving co-operation in medical and chemical research between workers in different countries and different disciplines. At its house in London the Foundation provides accommodation for scientists, organizes conferences, conducts a medical post-graduate exchange scheme between Great Britain and France, arranges a variety of informal discussions, awards two annual lecture-ships, and is building up a library service in special fields. The Foundation assists international congresses and scientific institutions, and it is hoped that in its hospitality, its meetings, and in such a volume as this, it is also usefully helping the individual scientist.

List of those participating in or attending the Symposium on
Drug Resistance in Micro-Organisms
26th-28th March, 1957

P. ALEXANDER	.	.	.	Chester Beatty Research Inst., London
MARY BARBER	.	.	.	Dept. of Bacteriology, St. Thomas's Hospital Medical School, London
ANN BISHOP	.	.	.	Molteno Inst. of Biology and Parasitology, University of Cambridge
L. L. CAVALLI-SFORZA	.	.	.	Istituto Sieroterapico Milanese, Milan
B. D. DAVIS	.	.	.	Dept. of Bacteriology and Immunology, Harvard Medical School, Boston
A. C. R. DEAN	.	.	.	Physical Chemistry Laboratory, Oxford
M. DEMEREC	.	.	.	Dept. of Genetics, Carnegie Inst. of Washing- ton, Cold Spring Harbor, Long Island, New York
H. EAGLE	.	.	.	Dept. of Experimental Therapeutics, National Inst. of Allergy and Infectious Diseases, Bethesda, Maryland
P. FREDERICQ	.	.	.	Dept. of Microbiology and Hygiene, University of Liège
J. D. FULTON	.	.	.	National Inst. for Medical Research, Mill Hill, London
B. GYÖRFFY	.	.	.	Inst. of Genetics, Hungarian Academy of Sciences, Budapest
SIR CHARLES HARINGTON	.	.	.	National Inst. for Medical Research, Mill Hill, London
P. HARTMAN	.	.	.	Dept. of Bacteriology and Immunology, Harvard Medical School, Boston; and Faculté des Sciences, Brussels
W. HAYES	.	.	.	Dept. of Bacteriology, Postgraduate Medical School, London
SIR CYRIL HINSHELWOOD	.	.	.	Physical Chemistry Laboratory, Oxford
R. D. HOTCHKISS	.	.	.	Rockefeller Inst. for Medical Research, New York
W. HOWARD HUGHES	.	.	.	Wright-Fleming Inst. for Microbiology, St. Mary's Hospital Medical School, London
N. D. IERUSALIMSKI	.	.	.	Inst. of Genetics, Academy of Sciences of the U.S.S.R., Moscow
R. KNOX	.	.	.	Dept. of Bacteriology, Guy's Hospital Medical School, London
K. V. KOSSIKOV	.	.	.	Inst. of Genetics, Academy of Sciences of the U.S.S.R., Moscow

W. KUNICKI-GOLDFINGER	.	Dept. of Microbiology, The University, Warsaw
J. LEDERBERG	.	The Medical School, Dept. of Medical Genetics, University of Wisconsin
ESTHER M. LEDERBERG	.	The Medical School, Dept. of Medical Genetics, University of Wisconsin
M. R. POLLOCK	.	National Inst. for Medical Research, Mill Hill, London
G. PONTECORVO	.	Dept. of Genetics, The University, Glasgow
F. L. ROSE	.	Research Dept. Chemical Group, Pharma- ceuticals Division, Imperial Chemical Industries Ltd., Manchester
P. SLONIMSKI	.	Laboratoire de Génétique Physiologique du C.N.R.S., Université de Paris
B. A. D. STOCKER	.	Lister Inst. of Preventive Medicine, London
J. WALKER	.	National Inst. for Medical Research, Mill Hill, London
M. WESTERGAARD	.	Dept. of Genetics, The University, Copen- hagen
J. YUDKIN	.	Dept. of Nutrition, Queen Elizabeth College, University of London

THE CIBA FOUNDATION

for the Promotion of International Co-operation in Medical and Chemical Research

41 PORTLAND PLACE, LONDON, W.1.

Trustees:

THE RIGHT HON. LORD ADRIAN, O.M., F.R.S.

THE RIGHT HON. LORD BEVERIDGE, K.C.B., F.B.A.

SIR RUSSELL BRAIN, Bt.

THE HON. SIR GEORGE LLOYD-JACOB

SIR RAYMOND NEEDHAM, Q.C.

Director, and Secretary to the Executive Council:

DR. G. E. W. WOLSTENHOLME, O.B.E.

Assistant to the Director:

DR. H. N. H. GENESE

Assistant Secretary:

MISS N. BLAND

Librarian:

MISS JOAN ETHERINGTON

Editorial Assistants:

MISS CECILIA M. O'CONNOR, B.Sc.

MISS MAEVE O'CONNOR, B.A.

ALL RIGHTS RESERVED

*This book may not be reproduced by
any means, in whole or in part, with-
out the permission of the Publishers*

Printed in Great Britain

CONTENTS

	PAGE
Chairman's opening remarks	
SIR CHARLES HARRINGTON	1
Aspects of the problem of drug resistance in bacteria	
<i>by</i> A. C. R. DEAN and SIR CYRIL HINSHELWOOD	4
<i>Discussion:</i> DEAN, EAGLE, HINSHELWOOD, LEDERBERG, POLLOCK, PONTECORVO	24
Indirect selection and origin of resistance	
<i>by</i> L. L. CAVALLI-SFORZA	30
<i>Discussion:</i> CAVALLI-SFORZA, DAVIS, DEAN, GYÖRFFY, HINSHELWOOD, HOTCHKISS, KUNICKI-GOLDFINGER, LEDERBERG, PONTECORVO, YUDKIN	40
Genetic aspects of drug resistance	
<i>by</i> M. DEMEREC	47
<i>Discussion:</i> ALEXANDER, DAVIS, DEMEREC, HINSHELWOOD, HOTCHKISS, LEDERBERG, POLLOCK, PONTECORVO, SLONIMSKI, WALKER, YUDKIN	58
Inheritance in single bacterial cells	
<i>by</i> W. HOWARD HUGHES	64
<i>Discussion:</i> CAVALLI-SFORZA, DAVIS, DEMEREC, EAGLE, HAYES, HUGHES, IERUSALIMSKY, LEDERBERG, PONTECORVO, STOCKER, YUDKIN	71
Penicillin-induced resistance to penicillin in cultures of <i>Bacillus cereus</i>	
<i>by</i> M. R. POLLOCK	78
<i>Discussion:</i> ALEXANDER, BARBER, DAVIS, HAYES, HOTCHKISS, KNOX, LEDERBERG, POLLOCK, PONTECORVO, SLONIMSKI, STOCKER	96
Directed hereditary changes of fermentative properties of yeast by a specific substrate	
<i>by</i> K. V. KOSSIKOV	102
<i>Discussion:</i> HARRINGTON, IERUSALIMSKY	136

	PAGE
Multiple mechanisms of acquired drug resistance	
<i>by</i> MARGARET J. THORNLEY, JEHUDITH SINAI and JOHN YUDKIN	141
<i>Discussion:</i> DAVIS, DEAN, FREDERICQ, FULTON, HOTCHKISS, HUGHES, POLLOCK, ROSE, SLONIMSKI, WALKER, YUDKIN	161
Physiological (phenotypic) mechanisms responsible for drug resistance	
<i>by</i> B. D. DAVIS	165
<i>Discussion:</i> DAVIS, EAGLE, KNOX, POLLOCK, PONTECORVO	180
Genetic and metabolic mechanisms underlying multiple levels of sulphonamide resistance in pneumococci	
<i>by</i> ROLLIN D. HOTCHKISS and AUDREY H. EVANS	183
<i>Discussion:</i> CAVALLI-SFORZA, DAVIS, DEMEREC, HOTCHKISS, LEDERBERG, PONTECORVO, STOCKER	193
The phenotypic expression of genes determining various types of drug resistance following their inheritance by sensitive bacteria	
<i>by</i> W. HAYES	197
<i>Discussion:</i> BARBER, CAVALLI-SFORZA, DAVIS, FREDERICQ, HAYES, HOTCHKISS, LEDERBERG, POLLOCK, PONTECORVO, STOCKER	205
Specific polyhydroxy compounds as cofactors of enzymic adaptation and its inheritance	
<i>by</i> P. P. SLONIMSKI and H. DE ROBICHON-SZULMAJSTER	210
<i>Discussion:</i> DAVIS, FULTON, POLLOCK, SLONIMSKI, WESTERGAARD	230
Development of resistance to streptomycin in <i>Serratia marcescens</i>	
<i>by</i> B. GYÖRFFY and I. KÁLLAY	233
<i>Discussion:</i> CAVALLI-SFORZA, DAVIS, DEAN, EAGLE, FULTON, GYÖRFFY, HAYES, HOTCHKISS, KNOX, LEDERBERG, STOCKER, YUDKIN	237
Distribution of drug-resistant individuals in cultures of <i>Mycobacterium tuberculosis</i>	
<i>by</i> R. KNOX	241
<i>Discussion:</i> DAVIS, DEAN, EAGLE, HAYES, KNOX, LEDERBERG, POLLOCK, PONTECORVO, STOCKER, WESTERGAARD	246

	PAGE
Physiological adaptation of bacteria to antibiotics	
<i>by</i> W. KUNICKI-GOLDFINGER	251
<i>Discussion:</i> ALEXANDER, DAVIS, GYÖRFFY, KNOX, KUNICKI-GOLDFINGER, LEDERBERG, SLONIMSKI, STOCKER, YUDKIN	259
Drug resistance of staphylococci with special reference to penicillinase production	
<i>by</i> MARY BARBER	262
<i>Discussion:</i> BARBER, BISHOP, CAVALLI-SFORZA, DAVIS, EAGLE, HAYES, HUGHES, KNOX, LEDERBERG, POLLOCK, PONTECORVO, WESTERGAARD	274
On the identification of genetic and non-genetic variation in bacteria	
<i>by</i> M. WESTERGAARD	280
<i>Discussion:</i> ALEXANDER, DAVIS, DEMEREC, HAYES, HUGHES, KNOX, LEDERBERG, PONTECORVO, ROSE, WESTERGAARD	290
The reactions of the mutagenic alkylating agents with proteins and nucleic acids	
<i>by</i> P. ALEXANDER, SHEILA F. COUSENS and K. A. STACEY	294
<i>Discussion:</i> ALEXANDER, DAVIS, HAYES, LEDERBERG, PONTECORVO, ROSE, WALKER, WESTERGAARD	318
Genetics of two different mechanisms of resistance to colicins: resistance by loss of specific receptors and immunity by transfer of colicinogenic factors	
<i>by</i> P. FREDERICQ	323
<i>Discussion:</i> CAVALLI-SFORZA, FREDERICQ, HAYES, LEDERBERG, POLLOCK, PONTECORVO, STOCKER	335
<i>General Discussion:</i> DAVIS, DEAN, HAYES, HOTCHKISS, LEDERBERG, POLLOCK, SLONIMSKI	339
Chairman's closing remarks	
SIR CHARLES HARINGTON	344

OPENING REMARKS

SIR CHARLES HARINGTON

IN spite of the great advances that have been made in recent years in the chemotherapeutic treatment of infectious diseases—advances that have brought under some measure of control the majority of protozoal and bacterial infections and some helminthic infections—the subject of chemotherapy remains distressingly empirical. The relationship between chemical structure and biological action in this field is still so ill-defined that we have only one significant guiding principle, based on biological theory, to help us in the search for new synthetic drugs for specific chemotherapeutic purposes. As for antibiotics the attempt to discover new substances of therapeutic value is admittedly based on no scientific principle at all, but is an operation such as oil prospecting would be with no adequate background of geological information.

Even when a new synthetic drug is discovered that proves to be of value in the treatment of a particular infection, it is usually impossible to explain the nature of the action of the drug; indeed the type of activity found is not infrequently quite different from that which is being sought, as is shown for instance by the discovery of a valuable antimalarial, pyrimethamine, in the course of a search for folic acid antagonists. Sometimes the drug proves not to have a direct action on the infecting organism at all, although it can suppress or cure the disease which the micro-organism causes; thus the anti-malarial drug proguanil has no direct lethal effect on plasmodia, but it is metabolized in the body of the host to a substance that has such an effect. Again hetrazan, which is the most effective remedy so far known for filariasis, does not kill the microfilariae directly but so alters them that they become susceptible to attack by the natural defence mechanisms of the host. The most striking example of such indirect chemotherapeutic action is afforded by the high-molecular surface-active

compounds that are curative of experimental tuberculosis and leprosy; in this instance there is clear evidence that the drugs, which are quite innocuous to the infecting organisms, confer on the monocytes of the host the power of inhibiting the growth of these organisms, thus exercising their effect by reinforcing the natural defence mechanisms of the host. The discovery of these drugs again was a totally unexpected outcome of the line of research that was being pursued.

All this means that the life of a chemist working in chemotherapy is apt to consist of long periods of unexciting work, punctuated if he is fortunate by occasional successes; even these successes however, whilst practically satisfying, may well be intellectually disappointing, since they will very likely bear little or no relation to the thought that he has put into his research.

By emphasizing as I have done the uncertainties and lack of fundamental knowledge that bedevil chemotherapy I must appear to have painted a very gloomy picture of the subject. If this is so, it is certainly not because I wish to say anything in disparagement of its importance. On the contrary, my object is to analyse the difficulties that we face, and which are particularly discouraging to chemists, in the attempt to see how they may be overcome.

It might be argued that in spite of all that I have said the situation is not unsatisfactory. New and effective chemotherapeutic agents continue to be discovered and the range of diseases brought under control increases. But so long as we cannot explain the reason for our successes we must remain scientifically dissatisfied, and there is one biological phenomenon, namely drug resistance, which makes the situation much less favourable than it appears even from a strictly utilitarian point of view. We can hardly be easy about a state of affairs in which it is reported that in many hospitals over 50 per cent of the strains of staphylococci causing infections have become resistant to penicillin, even though we now have other antibiotics with which they can be controlled; nor is the encouraging emptying of our tuberculosis sanatoria cause

for complacency, when we reflect that this would not be occurring had not the discovery of streptomycin been opportunely followed by those of the antituberculous effects of *p*-aminosalicylic acid and isoniazid. We cannot be sure that the searchers for new drugs and antibiotics will always win the race.

However hard and successfully we may work in the search for new drugs we shall therefore continue to labour under discouragement so long as we are faced with the bugbear of drug resistance. The problem is one of microbial biochemistry, physiology and genetics, and can only be solved by work in these fields. Until we understand the problem we shall have no hope of overcoming it, and until we overcome it we shall have no real sense of security in our chemotherapy. The subject of this symposium therefore is not only of the greatest scientific interest and importance; it has also a background of practical medical urgency, and I think we should do well to keep this thought in our minds.

There are, I am sure, plenty of chemists who would be eager to devote their abilities to research in chemotherapy if they could see it as a less empirical subject than it still is. This is obvious indeed from the mass of work that has resulted from the Woods-Fildes hypothesis of metabolic interference, a theory which, born by biochemistry out of microbiology, has been the most encouraging lead that the chemists have yet received from the biologist; it has systematized thought in the search for new drugs, and if its practical yield, apart from the folic acid antagonists, has so far been small, this is in my view because full fructification of the idea cannot be expected until microbiology is further advanced.

Now a further lead is needed, which can only come from the biochemists and the microbiologists. The greatest encouragement to chemical research would be the achievement of clearer insight into the development of drug resistance together with even a glimmering of an indication that this phenomenon may ultimately be subject to control. If our discussions bring nearer the day when a confident lead in this direction can be given our time will not have been wasted.

ASPECTS OF THE PROBLEM OF DRUG RESISTANCE IN BACTERIA

A. C. R. DEAN AND SIR CYRIL HINSHELWOOD

Physical Chemistry Laboratory, Oxford

General Observations

IN presenting this brief review of our present ideas on the subject of drug resistance it may be well to begin by mentioning views which have at one time or another been attributed to us, but which we have never held and of which no expression could be quoted from any of our publications.

We have never doubted that the essential characters of a cell are inherent in the structure of certain fundamental units including (though not necessarily exclusively) the deoxy-ribonucleic acid (DNA). We do not suppose these basic structures to be easily susceptible to change, and indeed in our experience easily provoked changes are normally destructive. The maintenance of species characters is of course a matter of the copying of the genetic patterns, and if and when these have been changed the heredity will be changed. We have never denied that structural mutations leading to increased drug resistance or improved utilization of nutrient sources can and do occur, or the obvious consequence that the mutants so arising would be rapidly selected in the appropriate environment.

On the other hand, we have contested the assumption that random mutation and selection is the sole mechanism (or perhaps even the major mechanism) for adaptation to new media or for the development of drug resistance. We have proposed more direct mechanisms, and quoted what appears to us to be good experimental evidence that in various specific examples these mechanisms operate.

Before outlining the proposed mechanisms and summarizing this evidence another point should be made clear. The primary concern of the work has been to explore the problem of the way in which cell reactions are co-ordinated, and the manner in which adjustments in the cell economy can take place, not to assert the relative importance of this or that evolutionary mechanism. A sound judgement on this latter question will probably be reached only when the number of examples studied is considerably greater than it is at present.

In quoting the kinds of evidence on which our current views are based we shall group together examples of adaptation to drugs and certain examples of adaptation to new substrates. The mechanisms will be often, though not always, the same. The addition of a drug to the medium often impedes certain essential enzyme reactions and so imposes a new reaction pattern on the cell. This is not unlike what happens when an unfamiliar substrate has to be used. On the other hand, drug resistance could arise, as in some cases phage resistance seems to, by a mutation leading to a deficiency whereby receptors for the drug in the cell are extirpated. In such a case the analogy with enzymic adaptation would be absent.

In its essentials the mechanism of adaptive change which we believe to operate in certain examples is the following. Although the major characters are determined by the basic gene structures, their quantitative expression is a function not merely of what structures are present but of the proportions in which they occur in the cell. When the medium is changed so that some parts of the reaction sequence are impeded relatively to others, corresponding changes in the relative proportions of the major cell constituents must occur. If division is governed even approximately by the attainment of a threshold amount of some key substance (and DNA seems to be roughly an invariant in this respect), then it is easily shown that the cell composition adjusts itself automatically to give an optimum growth rate.